Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Proteostasis Ther (PTI)

5.12 0.05 (0.99%)

04-20 16:00

Open:

5.05

Pre. Close:

5.07

High:

5.22

Low:

4.94

Volume:

542,507

Market Cap:

177M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

5.226 - 5.247

5.247 - 5.265

Low:

4.885 - 4.909

4.909 - 4.931

Close:

5.076 - 5.118

5.118 - 5.153

Technical analysis  (as of: 2018-04-20 4:32:55 PM)

Overall:

      

Stoxline posted a SELL today, same as yesterday. This stock seems to continue bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 7.26     One year: 8.61

Support:

Support1: 4.35    Support2: 3.62

Resistance:

Resistance1: 6.22    Resistance2: 7.38

Pivot:

4.93

Moving Averages:

MA(5): 5.18     MA(20): 4.93

MA(100): 4.34     MA(250): 3.60

MACD:

MACD(12,26): 0.14     Signal(12,26,9): 0.15

%K %D:

%K(14,3): 68.91     %D(3): 75.65

RSI:

RSI(14): 53.97

52-Week:

High: 8.61  Low: 1.41  Change(%): -6.6

Average Vol(K):

3-Month: 231985  10-Days 75515

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
PTI has closed below upper band by 32.0%. Bollinger Bands are 61.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to PTI's normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2018-04-17T08:43:13-04:00
TDN on board with Proteostasis' mid-stage study of cystic fibrosis candidate PTI-428

2018-04-17T07:10:00-04:00
Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko(TM) Therapy

2018-04-06T17:34:57-04:00
After Hours Gainers / Losers (04/06/2018)

2018-04-05T08:00:00-04:00
Your Daily Pharma Scoop: Tenax Surges, Eli Lilly's CYRAMZA, Cellectics Public Offering

2018-04-04T12:41:46-04:00
Midday Gainers / Losers (4/4/2018)

2018-04-04T09:17:40-04:00
Premarket Gainers as of 9:05 am (04/04/2018)

2018-04-04T06:23:14-04:00
Proteostasis Therapeutics receives Fast Track Designation for triple combination program in patients with cystic fibrosis

2018-04-04T06:00:00-04:00
Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

34.48

Shares Float (M)

34.06

% Held by Insiders

1.20

% Held by Institutions

54.70

Shares Short (K)

3178

Shares Short Prior Month (K)

Stock Financials

EPS

-2.350

EPS Est. Current Year

-2.750

EPS Est. Next Year

-2.450

EPS Est. Next Quarter

-0.750

Forward EPS

-2.177

Book Value (p.s.)

2.530

PEG Ratio

Profit Margin

Operating Margin

-1122.88

Return on Assets (ttm)

-64.1

Return on Equity (ttm)

-79.1

Qtrly Rev. Growth

-60.0

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-1.342

Qtrly Earnings Growth

Operating Cash Flow (M)

-52.40

Levered Free Cash Flow (M)

-29.92

atoplab.com

Valuation

P/E

-2.18

P/E Growth Ratio

0.01

P/BV

2.02

P/S

840655232.00

P/CF

-3.37

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.